Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine niche and are considered stock leaders.
6 reports, 2 independent
Updated Aug 14
Gone quiet
- Reports
- 6
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine niche and are considered stock leaders.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Hims & Hers and Eucalyptus expand internationally through a partnership granting access to branded GLP-1 medications.Sub-event
Eli Lilly, Novo Nordisk, and Amgen are leading the weight-loss medicine market.1 source
Companies are intensifying competition in the weight loss drug market, with Amgen also expanding its rare disease business.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Amgen
American multinational biopharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.